The History Of CJC 1295
CJC 1295 has a rather short albeit incredibly confusing history owing to the multiple names this product has been referred to over the minimal time frame it has been in existence for.
We’ll first start by stating that Canadian pharmaceutical company ConjuChem, as a means of optimising biotechnology improvements, created CJC 1295.
Initial trials with this product began in the mid 2000’s – the earliest tests performed appeared to be in 2008 according to the scarce records available in regards to this items timeline.
These tests all revolved around stimulating chemicals in animal test subjects as well as deciphering and trying to gain a firm understanding of the unique health benefits that may arise as a result of such stimulation.
During this early period of CJC 1295’s development, one of the glaringly obvious downfalls of the base formula was its tremendously short half-life.
This ultimately lead to an emphasis being placed on finding a means to extend it in order to make the compound more functionally “appropriate.”
In order to fulfil this end result, scientists had to fully understand the precise mechanism of action it carried out in order to exert its effects so that they could improve the base formula.
Rarely (typically a pharma company will have to create a product from scratch), this base formula already existed. Whilst ConjuChem definitely “invented” CJC 1295, they did not necessarily create something entirely original when they unleashed it on the medical research community.
CJC 1295’s Identity Crisis
The origins of the CJC 1295 “blueprint” can be traced back to the discovery and synthesization of growth hormone releasing hormone itself dating back to the 1980’s. This ultimately lead to the creation of the GHRH 1-29 complex that CJC 1295 is based on.
You may already have seen this formula listed for sale as GRF 1-29, or by its other popular name “mod GRF 1-29.”
This is where the aforementioned confusion starts to come into play. This is because “mod GRF1-29” is actually CJC 1295 without DAC. The two are exactly the same product, though they are often listed by either name on retail sites.
This confusion is not helped by the fact that GRF 1-29 (not to be mistaken with mod GRF) is also a completely separate product that almost always goes under the name “sermorelin” in the commercial sector.
CJC 1295 is none of these three mentioned products and sits in its own “corner.”
Whenever you see CJC 1295 mentioned with the addition of “without DAC”, this means by default that it is the “standard” version of CJC 1295 with DAC included.
The difference between sermorelin and mod GRF 1-29 are explained in full on their individual profiles, but what it’s important to understand at this stage is that CJC 1295 is a modified variant of the modified (mod GRF 1-29) version of GRF 1-29 (or sermorelin.)
This makes it a second-generation growth hormone secretagogue.
Medical Uses Of CJC 1295
Though CJC 1295 and all other secretagogues have not been condoned for human use officially by the FDA – they are currently allowed for medical research purposes.
To date, the majority of testing that has taken place has been carried out on animals – human test information is scarce to say the least though there are a handful of examples, including this one performed between 2006 – 2007.
Through observing the properties of CJC 1295, it’s not difficult to understand how it would be applied within a medical capacity.
It could be used to:
- Treat patients with growth hormone releasing hormone dysfunction
- Treat patients who were in need of assistance with cell regeneration following a degenerative disease
- Improve overall vitality in patients who are suffering from the effects of aging
- Assist patients who are suffering with adverse bone / joint issues
With these areas in mind, it’s a shame that growth hormone secretagogues haven’t yet been condoned for human use, because they could actually prove to be highly beneficial.
On balance, the FDA can’t approve products like CJC 1295 until further human testing commences and positively concludes.
This is fairly unlikely to happen owing to the enormous crackdown on anabolic substances of all types ever since the East German doping scandal in the early 1990’s.
Following this notorious event, any compound that was associated with athletic / bodybuilding use or could potentially be integrated into such a circle was ostracised from widespread medical circulation.
Ever since, there has been a general “unease” in regards to products of this nature being freely authorised for human use. This is the “catch 22” situation we find ourselves in regarding these products becoming freely available.
It’s also worth noting that due to the fact that both growth hormone and sermorelin (a growth hormone releasing hormone secretagogue in its own right) are already approved (and arguably fulfil the majority of the previously outlined benefits), it’s going to be difficult for anyone to convince the FDA that surplus secretagogues of this nature are actually needed.
For now at least, our only human “research” data is going to come from the bodybuilding and athletic communities as they continue to experiment with CJC 1295 and many other peptides and relay their findings back to us.
Sandor Earle – The Famous CJC 1295 Doping Case
The Rugby league player Sandor Earl was found guilty of using CJC 1295 to help rehabilitate his shoulder following reconstructive surgery in 2015.
This particular case is quite well known due to the severity of his ban; he faced four years suspension as a result of not only his personal use, but the fact that he was believed to have been trafficking too.
His total list of charges included:
- Trafficking in Somatropin
- Trafficking in Clenbuterol
- Use of CJC-1295 (eight violations)
- Possession of CJC-1295
- Attempted trafficking in testosterone
- Attempted trafficking in SARMS
Some believed that his sentence duration was excessive being that, shortly before his case in 2011 members of the Cronulla squad had only been suspended for roughly twelve months (which worked out at only three games over the course of the ban.)
However, the severity of Sandors sentencing was largely down to the trafficking charges – had he simply been caught using CJC 1295 it is unlikely that he would have faced anything more than a 12 month ban.
The reason why we elaborate on the separate charges here is to help you understand the difference in terms of potential repercussions between personal use and distribution.
Should you be a sportsperson playing at a professional level (up to or equivalent of Sandor’s) then it’s imperative that you consider this scenario and factor it into any decisions you make regarding the use of performance enhancing compounds like CJC 1295.
Typically, the higher the level you are playing at, the higher the chance that your substance utilisation will be detected due to advanced testing techniques.
In this instance, Sandor admitted use following suspicion. Whether or not he would have got away with utilising or providing these items had he shown more caution is entirely open to interpretation.